Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE
    • Publication Information:
      Publication: 2004- : Chichester, West Sussex, England : Wiley
      Original Publication: Oxford, U.K. ; Vista, CA : Update Software,
    • Subject Terms:
      Arthritis, Infectious/*pathology ; Arthritis, Rheumatoid/*pathology ; Joint Diseases/*pathology ; Smoking/*adverse effects ; Smoking Cessation/*methods; Cognitive Behavioral Therapy ; Humans ; Osteoarthritis/pathology ; Quality of Life ; Randomized Controlled Trials as Topic ; Spondylarthritis/pathology
    • Abstract:
      Background: Chronic inflammatory joint diseases (IJDs) affect 1% to 2% of the population in developed countries. IJDs include rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other forms of spondyloarthritis (SpA). Tobacco smoking is considered a significant environmental risk factor for developing IJDs. There are indications that smoking exacerbates the symptoms and worsens disease outcomes.
      Objectives: The objective of this review was to investigate the evidence for effects of smoking cessation interventions on smoking cessation and disease activity in smokers with IJD.
      Search Methods: We searched the Cochrane Tobacco Addiction Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Library; PubMed/MEDLINE; Embase; PsycINFO; the Cumulative Index to Nursing and Allied Health Literature (CINAHL); and three trials registers to October 2018.
      Selection Criteria: We included randomised controlled trials testing any form of smoking cessation intervention for adult daily smokers with a diagnosis of IJD, and measuring smoking cessation at least six months after baseline.
      Data Collection and Analysis: We used standard methodological procedures as expected by Cochrane.
      Main Results: We included two studies with 57 smokers with a diagnosis of rheumatoid arthritis (RA). We identified no studies including other IJDs. One pilot study compared a smoking cessation intervention specifically for people with RA with a less intensive, generic smoking cessation intervention. People included in the study had a mean age of 56.5 years and a disease duration of 7.7 years (mean). The second study tested effects of an eight-week cognitive-behavioural patient education intervention on cardiovascular disease (CVD) risk for people with RA and compared this with information on CVD risk only. The intervention encouraged participants to address multiple behaviours impacting CVD risk, including smoking cessation, but did not target smoking cessation alone. People included in the study had a mean age of 62.2 years (intervention group) and 60.8 years (control group), and disease duration of 11.6 years (intervention group) and 14.1 years (control group). It was not appropriate to perform a meta-analysis of abstinence data from the two studies due to clinical heterogeneity between interventions. Neither of the studies individually provided evidence to show benefit of the interventions tested. Only one study reported on adverse effects. These effects were non-serious, and numbers were comparable between trial arms. Neither of the studies assessed or reported disease activity or any of the predefined secondary outcomes. We assessed the overall certainty of evidence as very low due to indirectness, imprecision, and high risk of detection bias based on GRADE.
      Authors' Conclusions: We found very little research investigating the efficacy of smoking cessation intervention specifically in people with IJD. Included studies are limited by imprecision, risk of bias, and indirectness. Neither of the included studies investigated whether smoking cessation intervention reduced disease activity among people with IJD. High-quality, adequately powered studies are warranted. In particular, researchers should ensure that they measure disease markers and quality of life, in addition to long-term smoking cessation.
    • References:
      Rheumatology (Oxford). 2000 Nov;39(11):1202-5. (PMID: 11085797)
      Clin Rheumatol. 2015 Mar;34(3):579-83. (PMID: 25024097)
      Arthritis Care Res (Hoboken). 2017 Jan;69(1):28-37. (PMID: 27333261)
      PLoS One. 2015 Feb 17;10(2):e0117952. (PMID: 25689371)
      Trials. 2013 Oct 09;14:324. (PMID: 24103529)
      BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
      J Rheumatol. 1994 Dec;21(12):2286-91. (PMID: 7699630)
      Arthritis Rheum. 2012 May;64(5):1388-98. (PMID: 22127957)
      Ann Rheum Dis. 2009 Jun;68 Suppl 2:ii1-44. (PMID: 19433414)
      Ann Rheum Dis. 2012 Sep;71(9):1524-9. (PMID: 22425941)
      Ann Rheum Dis. 2017 Jan;76(1):17-28. (PMID: 27697765)
      Osteoporos Int. 2010 Aug;21(8):1287-93. (PMID: 20229200)
      Int J Mol Sci. 2014 Dec 03;15(12):22279-95. (PMID: 25479074)
      PLoS One. 2015 Apr 08;10(4):e0123582. (PMID: 25853482)
      Rheumatology (Oxford). 2008 Jun;47(6):849-54. (PMID: 18390589)
      Rheumatology (Oxford). 2014 Feb;53(2):213-22. (PMID: 23946436)
      Ann Rheum Dis. 2002 Jan;61(1):66-9. (PMID: 11779763)
      Rheumatology (Oxford). 2015 Aug;54(8):1528-30. (PMID: 26018439)
      Musculoskeletal Care. 2016 Mar;14(1):2-14. (PMID: 25982887)
      Trials. 2010 May 12;11:52. (PMID: 20462436)
      Am J Cardiovasc Drugs. 2016 Feb;16(1):1-8. (PMID: 26293235)
      Rheumatol Int. 2014 Jan;34(1):93-9. (PMID: 24005567)
      Ann Rheum Dis. 2009 Jan;68(1):18-24. (PMID: 18625618)
      Arthritis Rheum. 2009 Jul 15;61(7):859-66. (PMID: 19565552)
      J Cardiothorac Vasc Anesth. 1997 Aug;11(5):629-40. (PMID: 9263101)
      Clin Ther. 2016 May;38(5):1205-16. (PMID: 27045991)
      Ann Rheum Dis. 2012 Jun;71(6):809-16. (PMID: 21989541)
      J Rheumatol. 1994 Dec;21(12):2281-5. (PMID: 7699629)
      Patient Educ Couns. 2011 Jul;84(1):123-7. (PMID: 20638217)
      Curr Opin Cardiol. 2011 Jul;26(4):327-33. (PMID: 21499088)
      Rheumatology (Oxford). 2013 Jan;52(1):81-90. (PMID: 22942402)
      Open Rheumatol J. 2012;6:303-9. (PMID: 23115602)
      Lancet. 2010 Sep 25;376(9746):1094-108. (PMID: 20870100)
      Ann Rheum Dis. 2011 Jan;70(1):25-31. (PMID: 21109520)
      Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7. (PMID: 15708927)
      Arthritis Care Res (Hoboken). 2018 Jun;70(6):823-833. (PMID: 29024454)
      Ann Rheum Dis. 2011 Jan;70(1):47-53. (PMID: 21068095)
      Cochrane Database Syst Rev. 2017 Dec 15;12:CD001188. (PMID: 29243221)
      Arthritis Rheum. 2006 Aug;54(8):2665-73. (PMID: 16871531)
      Arthritis Rheum. 1984 Apr;27(4):361-8. (PMID: 6231933)
      Curr Opin Rheumatol. 2016 Sep;28(5):497-505. (PMID: 27428889)
      Curr Opin Rheumatol. 2009 May;21(3):279-83. (PMID: 19318947)
      Arthritis Rheum. 2006 Jan;54(1):38-46. (PMID: 16385494)
      Nat Rev Immunol. 2002 May;2(5):372-7. (PMID: 12033743)
      Trials. 2017 Nov 28;18(1):570. (PMID: 29183347)
      J Rheumatol. 2003 Apr;30(4):880-3. (PMID: 12672221)
      J Clin Rheumatol. 2019 Oct;25(7):288-296. (PMID: 29994796)
      BMJ. 2011 Oct 18;343:d5928. (PMID: 22008217)
      Rheumatology (Oxford). 2016 Apr;55(4):659-68. (PMID: 26628579)
      Lancet. 2004 Feb 28;363(9410):675-81. (PMID: 15001324)
      Arthritis Care Res (Hoboken). 2018 Jan;70(1):19-29. (PMID: 28464477)
      Joint Bone Spine. 2018 Mar;85(2):135-138. (PMID: 29246527)
      Arthritis Care Res (Hoboken). 2013 Jan;65(1):78-87. (PMID: 22514159)
      Joint Bone Spine. 2013 May;80(3):234-5. (PMID: 23238005)
      Autoimmun Rev. 2010 Mar;9(5):A288-92. (PMID: 19944780)
      Am J Gastroenterol. 2012 Sep;107(9):1407-8. (PMID: 22951878)
      Musculoskeletal Care. 2018 Mar;16(1):74-81. (PMID: 28681572)
      Arthritis Care Res (Hoboken). 2022 Sep;74(9):1421-1429. (PMID: 33825349)
      Arthritis Rheum. 1995 Jan;38(1):44-8. (PMID: 7818570)
      RMD Open. 2017 Sep 26;3(2):e000506. (PMID: 29018566)
      Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004722. (PMID: 15495126)
      Clin Rheumatol. 2008 Feb;27(2):141-5. (PMID: 17912575)
      Scand J Gastroenterol Suppl. 1989;170:61-3; discussion 66-8. (PMID: 2617195)
      J Rheumatol. 2016 Apr;43(4):691-8. (PMID: 26879360)
      Ann Rheum Dis. 2010 Sep;69(9):1580-8. (PMID: 20699241)
      Cochrane Database Syst Rev. 2015 Mar 02;(3):CD006936. (PMID: 25726920)
      Rheumatology (Oxford). 2016 Nov;55(11):1969-1977. (PMID: 27477806)
      J Rheumatol. 2005 Jan;32(1):80-5. (PMID: 15630730)
      Ann Rheum Dis. 2016 Mar;75(3):499-510. (PMID: 26644232)
      Ann Rheum Dis. 2015 Sep;74(9):1725-33. (PMID: 24872377)
      Cochrane Database Syst Rev. 2013 May 31;(5):CD000165. (PMID: 23728631)
      Expert Rev Clin Immunol. 2013 Jun;9(6):511-6. (PMID: 23730882)
    • Publication Date:
      Date Created: 20190903 Date Completed: 20191017 Latest Revision: 20240902
    • Publication Date:
      20240902
    • Accession Number:
      PMC6718206
    • Accession Number:
      10.1002/14651858.CD012958.pub2
    • Accession Number:
      31476270